These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 29185227)

  • 1. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 5. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):419-424. PubMed ID: 32482033
    [No Abstract]   [Full Text] [Related]  

  • 11. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
    Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
    Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario?
    Rana AKS; Agarwal N; Dutta S; Dokania MK; Goyal H
    J Gastrointest Cancer; 2019 Dec; 50(4):983-990. PubMed ID: 30140971
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study.
    Stearns AT; Malcomson L; Punnett G; Abudeeb H; Aziz O; Selvasekar CR; Fulford PE; Wilson MS; Renehan AG; O'Dwyer ST
    Ann Surg Oncol; 2018 Apr; 25(4):965-973. PubMed ID: 29313146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
    Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
    World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
    Sugarbaker PH
    Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
    Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
    Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
    Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
    Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
    Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A
    J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.